HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,453,211 | +20.5% | 324,707 | +13.3% | 1.28% | +27.0% |
Q2 2023 | $10,333,694 | -6.3% | 286,490 | +0.3% | 1.00% | -9.2% |
Q1 2023 | $11,028,310 | -32.6% | 285,722 | -0.3% | 1.11% | -33.8% |
Q4 2022 | $16,367,967 | +30.6% | 286,523 | -9.2% | 1.67% | +19.5% |
Q3 2022 | $12,529,000 | -5.0% | 315,584 | +5.3% | 1.40% | -1.5% |
Q2 2022 | $13,192,000 | +58.2% | 299,825 | +33.3% | 1.42% | +66.0% |
Q1 2022 | $8,338,000 | -26.5% | 224,849 | -19.5% | 0.86% | -24.7% |
Q4 2021 | $11,338,000 | -4.0% | 279,423 | -3.8% | 1.14% | -4.6% |
Q3 2021 | $11,813,000 | -6.1% | 290,394 | +4.9% | 1.19% | -2.5% |
Q2 2021 | $12,575,000 | +12.2% | 276,912 | +3.0% | 1.22% | +4.7% |
Q1 2021 | $11,211,000 | +8.7% | 268,917 | +11.4% | 1.17% | -10.5% |
Q4 2020 | $10,309,000 | +32.8% | 241,362 | -17.5% | 1.30% | +32.9% |
Q3 2020 | $7,761,000 | -1.0% | 292,570 | +0.9% | 0.98% | -3.9% |
Q2 2020 | $7,840,000 | +53.2% | 290,087 | +2.1% | 1.02% | +20.8% |
Q1 2020 | $5,118,000 | – | 284,143 | – | 0.84% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |